<em class="pub-author">EMCDDA,</em> <em class="pub-local">Lisbon,</em> <em class="pub-date"><span class="date-display-single" property="dc:date" datatype="xsd:dateTime" content="2020-11-13T00:00:00+00:00">November 2020</span></em> <div class="summary"> <h2 class="publications-summary">Summary</h2> <div class="field field-name-field-summary field-type-text-long field-label-hidden"><div class="field-items" readability="10.5"><div class="field-item even" readability="16">This publication presents the data and findings of the risk assessment on <em>N,N</em>-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1<em>H</em>-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020. On the basis of the Risk Assessment Report, on 2 September 2020, the Commission decided that isotonitazene should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA. Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with Commission Delegated Directive (EU) 2020/1687 by 3 June 2021.
Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)
DISCLAIMER: Information and opinions reproduced in the articles are the ones of those stating them and it is their own responsibility. Publication in The European Times does not automatically means endorsement of the view, but the right to express it.
DISCLAIMER TRANSLATIONS: All articles in this site are published in English. The translated versions are done through an automated process known as neural translations. If in doubt, always refer to the original article. Thank you for understanding.
<div class="publication-attachments pdf"> <strong>Download as PDF</strong> </div> <div> <div class="publication-toc"><h2>Table of contents</h2><ul><li>Statement regarding the United Kingdom</li> <li>Foreword</li> <li>EMCDDA Initial Report on isotonitazene</li> <li>Risk Assessment Report on a new psychoactive substance: isotonitazene</li> <li>Technical report on isotonitazene</li> <li>Participants of the risk assessment meeting, 26 May 2020</li>
<div class="main-subject"><h3 class="field-label"><i class="fa fa-tag"/> Main subject: </h3><p class="field-items"><span class="field-item">NPS</span></p></div>